Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Servier Pharmaceuticals LLC manages a portfolio with 6 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 6 distinct examiners, showing variety in the individuals reviewing the company's applications. The presence of 6 actions across 6 different examiners means that every pending matter is currently assigned to a unique person.
These examiners are situated within 5 distinct art units. The ratio of 6 examiners to 5 art units indicates that multiple examiners are working within the same art unit, while others are spread across the remaining units. This distribution suggests that while the technology area is consistent, the specific technical focuses of the applications vary enough to trigger different art unit assignments.
HAMA, JOANNE is the busiest examiner for this portfolio, currently holding 1 busiest examiner pending action. Since the total number of pending office actions is 6 and the busiest examiner only accounts for 1, the workload is balanced among the 6 distinct examiners. No single examiner exerts more influence over the portfolio than any other, as each is responsible for exactly one of the total pending actions.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAMA, JOANNE | 1 | 25.7% | +40.0% |
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
| CHICKS, ASHLI ARIANA | 1 | 60.6% | +50.3% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18193958 | METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY | HAMA, JOANNE | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18193958 | METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY | HAMA, JOANNE | 23d overdue |
| 18053332 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | CHICKS, ASHLI ARIANA | 4d overdue |
| 18053326 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | ROBINSON, MIKHAIL O'DONNEL | 34d |
| 18111511 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | KOMATSU, LI N | — |
| 18015396 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1647 | 1 |
| 1658 | 1 |
| 1693 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18193958 | METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY | HAMA, JOANNE | 1647 | §103Other | Non-Final OA | 23d overdue | Pending | Mar 31, 2023 |
| 18111511 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | KOMATSU, LI N | 1658 | DP | Non-Final OA | — | Pending | Feb 17, 2023 |
| 18015396 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | HERNANDEZ, JACKSON J | 1627 | §103Other | Non-Final OA | — | Pending | Jan 10, 2023 |
| 17999400 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | OLSON, ANDREA STEFFEL | 1693 | §102 | Final Rejection | 5d overdue | Pending | Nov 20, 2022 |
| 18053332 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | CHICKS, ASHLI ARIANA | 1626 | §103DP | Non-Final OA | 4d overdue | Pending | Nov 07, 2022 |
| 18053326 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102§103DP | Final Rejection | 34d | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial